Evaluation of the prevalence of minimal hepatic encephalopathy in patients with compensated cirrhosis by Yoganandh, T
  EVALUATION OF PREVALENCE OF MINIMAL 
HEPATICL ENCAPHALOPATHY IN PATIENTS  WITH 
COMPENSATED CIRRHOSIS 
 
Dissertation submitted to  
THE TAMILNADU Dr. M. G. R. MEDICAL UNIVERSITY  
MD Degree in General Medicine 
Branch I 
 
Chennai  
March 2010 
 
 
 DEPARTMENT OF GENERAL MEDICINE 
Coimbatore Medical College Hospital. 
Coimbatore 
                                 CERTIFICATE 
This is to certify that the Dissertation entitled “EVALUATION 
OF THE PREVALENCE OF MINIMAL HEPATIC 
ENCEPHALOPATHY IN PATIENTS WITH COMPENSATED 
CIRRHOSIS” here with submitted by Dr. T.YOGANANDH, Post 
graduate in General Medicine, Coimbatore Medical College to the 
Tamilnadu Dr.M.G.R Medical University is a record of a bonafide 
research work carried out by him under my guidance and supervision 
from June 2008 to May 2009. 
 
 
Dr. VEERAKESARI, MD   Dr. UMAKANTHAN, MD 
Professor & Unit chief,    Professor & Head, 
Department of Medicine.    Department of Medicine. 
 
 
DEAN 
Coimbatore Medical College 
Coimbatore 
  
DECLARATION 
 
I solemnly declare that the Dissertation titled “EVALUATION 
OF THE PREVALENCE OF MINIMAL HEPATIC 
ENCEPHALOPATHY IN PATIENTS WITH COMPENSATED 
CIRRHOSIS,” was done by me at Coimbatore Medical College and 
Hospital during the period from June ’08 to July ’09 under the 
guidance and supervision of Prof. Dr. Veerakesari,M.D. 
 
This dissertation is submitted to the Tamil Nadu Dr. M.G.R 
Medical University towards the partial fulfillment of the requirement 
for the award of MD Degree (Branch I) in General Medicine. 
 
 
 
Place : Coimbatore      
Date  :                                               Dr.T.YOGANANDH 
  
 ACKNOWLEDGEMENT 
 ACKNOWLEDGEMENT 
 
I am greatly indebted to Dr.Kumaran M.ch., Dean, Coimbatore 
Medical College whose permission is the light house of this study. 
I thank Dr. Umakanthan M.D., Professor and Head of the 
Department, Medicine whose energetic endeavor inspired me to do this 
study.  
I thank Dr. Veerakesari M.D, Professor and unit chief for his 
constant support and interest in conduction of the study and his 
encouragement as well as constructive criticism enabled me to perform 
this study in a better way. With his kind permission, I have been able to 
study his ward patients well. I am indebted to these patients for their 
cooperation. 
I thank Dr. Ramasamy MD., & Dr.Nedumaran M.D.,D.M., 
Professors of Medicine for their guidance and help.  
I thank sincerely thank Dr.K.Govindarajan M.D., DM, Professor 
and Head of the Department of Neurology for guiding me to formulate 
the plan of the study. 
 My deep and sincere thanks to Dr.RAVISHANKER, Professor of 
Medical Gastroenterology for his participation in this study without any 
hesitation and the encouragement made this study successful.  
I thank  Prof.PRABAKARAN M.D. (Psychiatry) , Professor and 
HOD, and the Assistant Professors of Department of Psychiatry for 
guiding me in conducting the Neuropsychiatric assessment. 
I also extend my thanks to Dr.Ramkumar, Dr.Raveendran and 
Dr.Geetha, Assistant Professors of Medicine for their kind co-operation 
and assistance at various stages of this study. 
I convey my thanks to Dr.N.Neelambikai  Professor and Head of 
Department of Physiology and Secretary of Ethics Committee and other 
members of the Ethics Committee for their suggestions in doing this 
study.  
I would like to convey my thanks to all my colleagues for their 
help and co-operation.  
I am grateful to all the patients who have participated in this study.
 CONTENTS 
 
S.No             Page No 
 
1.  Introduction      1  
2.  Aim of the study     2 
3.  Review of Literature    3 
4.  Material & Methods    52 
5.  Results & Analysis    53 
6.  Discussion      61 
7.  Conclusion      64 
8.  Bibliography     i - vii 
 
 
 
  
 
 
 
 
INTRODUCTION 
 1.  INTRODUCTION 
Hepatic encephalopathy(HE) is a leading cause of morbidity and 
mortality in patients with Cirrhosis of liver and can its manifested with 
subtle alterations in neurocognitive functions or with depressed level of 
consciousness.1,2 
Hepatic encephalopathy is a leading cause of morbidity and 
mortality in patients with cirrhosis and other porto-systemic shunting of 
intestinal blood4 
Minimal Hepatic Encephalopathy (MHE) is now well established 
phenomenon and is defined as the condition in which patients with liver 
cirrhosis show several quantifiable neuropsychological defects but with a 
normal neurological examination.3 
Identification of MHE is now possible with easily available 
neuropsychiatric methods and treatment should be promptly instituted to 
prevent further deterioration.  
 
 
  
 AIM OF THE STUDY 
 2. AIM OF THE STUDY 
The objectives of this study are: 
1. To evaluate the prevalence of cognitive and performance 
impairment in patients with compensated cirrhosis of liver. 
2. To evaluate the Electro Encephalographic abnormalities as a 
marker of cerebral cortical involvement in such patients using 
EEG. 
3. To assess the prevalence of Minimal Hepatic Encephalopathy in 
compensated cirrhotics by using Psychometric testing and EEG. 
 
 
 
 
 
 
 
 
 
  
  
 
 
REVIEW OF LITERATURE 
 3. REVIEW OF LITERATURE  
3.1 DEFINITION  
Hepatic encephalopathy (HE) is a neuropsychiatric disorder that 
may accompany either acute or chronic liver disease. It is defined as a 
disturbance of central nervous system function due to hepatic 
insufficiency and includes a large spectrum of clinical manifestations 
such as decreased intellectual function, personality disorders, alterations 
in the level of consciousness and neuromuscular dysfunctions.5 
HE can be classified into 3 major clinical types: 
a. HE associated with acute liver failure. 
b. HE associated with portal systemic bypass and no intrinsic 
hepatocellular disease. 
c. HE associated with cirrhosis and portal hypertension/ or 
portal-systemic shunts. 
HE associated with cirrhosis and portal hypertension/ or portal 
systemic shunts is classified further as 
I.   Episodic HE 
II.  Persistent HE 
 III. Minimal -or subclinical- HE (MHE)6 
 MHE is defined as the condition in which patients with liver 
cirrhosis show several quantifiable neuropsychological defects with a 
normal neurological examination. 
3.2 CIRRHOSIS – AN OVERVIEW 
 In order to understand Hepatic Encephalopathy and its 
antecedent Minimal Hepatic Encephalopathy an understanding of 
cirrhosis and other complications is needed. 
3.2.1 DEFINITION 
 Cirrhosis is defined histologically as a diffuse hepatic 
process characterized by fibrosis and the conversion of normal liver 
architecture into structurally abnormal nodules.16 
3.2.2 EPIDEMIOLOGY  
 Cirrhosis and chronic liver disease accounts for 26,000 to 
35,000 deaths per annum in India and 2000 additional cases of  Fulminant 
Hepatic Failure (FHF) die every year. FHF can be caused by drugs 
(acetaminophen), Post Infectious (Hepatitis A & B), Wilson disease and 
various other common causes. Cryptogenic cases account for about a 
 third of these cases of FHF. The mortality is very high (50% - 80%) 
unless salvaged by liver transplant. 
3.2.3 ETIOLOGY 
 In India, causes of cirrhosis vary from that of Western 
World.  
While in the countries like the US Hepatitis is a leading cause, 
alcohol remains common in India. 
¾ Alcoholic Liver disease (35%) 
¾ Post-Infectious causes (30%) 
¾ Cryptogenic causes (18%) 
¾ Post hepatic and biliary causes (8%) 
¾ Miscellaneous (9%) 
Cirrhosis is said to be compensated when manifestations of liver 
failure are absent. Those patients with signs of liver cell failure or its 
complications are classified as decompensated cirrhotics 
Miscellaneous causes of chronic liver disease and cirrhosis  
• Autoimmune hepatitis 
• Primary biliary cirrhosis 
 • Secondary biliary cirrhosis (associated with chronic extrahepatic 
bile duct obstruction) 
• Primary sclerosing cholangitis 
• Hemochromatosis 
• Wilson disease 
• Alpha-1 antitrypsin deficiency 
• Granulomatous disease (eg, sarcoidosis) 
• Type IV glycogen storage disease 
• Drug-induced liver disease (eg, methotrexate, alpha methyldopa, 
amiodarone) 
• Venous outflow obstruction (eg, Budd-Chiari syndrome, veno-
occlusive disease) 
• Chronic right-sided heart failure 
• Tricuspid regurgitation 
3.2.4 PATHOPHYSIOLOGY OF CIRRHOSIS 
Normal liver extracellular matrix, the normal scaffolding for 
hepatocytes, is composed of collagens (especially types I, III, and V), 
glycoproteins, and proteoglycans. The development of hepatic fibrosis 
reflects an alteration in the normally balanced processes of extracellular 
matrix production and degradation. Whenever there is any injury to the 
 hepatic cells by way of toxins, alcohol etc, there are characteristic 
changes. 
Stellate cells, located in the perisinusoidal space, are essential for 
the production of extracellular matrix. Paracrine factors may be released 
by hepatocytes, Kupffer cells, and sinusoidal endothelium following liver 
injury. As an example, increased levels of the cytokine transforming 
growth factor beta1 (TGF-beta1) is observed in patients with cirrhosis. 
TGF-beta1, in turn, stimulates activated stellate cells to produce type I 
collagen. 
Future drug strategies to prevent fibrosis may focus on reducing 
hepatic inflammation, inhibiting stellate cell activation, inhibiting the 
fibrogenic activities of stellate cells, and stimulating matrix degradation. 
 The small finely nodular liver of micronodular cirrhosis 
 Macronodular cirrhosis 
 3.2.5 HISTOLOGY 
The final and irreversible form of liver disease usually evolves 
slowly and insidiously. At first the cirrhotic liver is yellow-tan, fatty, and 
enlarged, usually weighing over 2 kg. Over the span of years it is 
transformed into a brown, shrunken, nonfatty organ, sometimes weighing 
less than 1 kg.  
Cirrhosis may develop more rapidly in the setting of alcoholic 
hepatitis, within 1 to 2 years. Regenerative activity of entrapped 
parenchymal hepatocytes generates fairly uniformly sized nodules. Since 
these nodules tend to be less than 0.3 cm in diameter, this pattern of 
cirrhosis is termed micronodular cirrhosis (vs. the macronodular 
cirrhosis described for viral hepatitis). Scattered larger nodules create a 
"hobnail" appearance on the surface of the liver. As fibrous septa dissect 
and surround nodules, the liver becomes more fibrotic, loses fat, and 
shrinks progressively.  
    
  Micronodular cirrhosis. Gross fatty change.  
Ischemic necrosis and fibrous obliteration of nodules eventually 
create broad expanses of tough, pale scar tissue. Bile stasis often 
develops; Mallory bodies are  rarely evident at this stage. Thus, end-stage 
alcoholic cirrhosis eventually comes to resemble, both macroscopically 
and microscopically, the cirrhosis developing from viral hepatitis and 
other causes. 
3.2.6 CLINICAL FEATURES 
Patients with alcoholic liver disease can present with nonspecific 
symptoms such as vague right upper quadrant pain, fever, nausea and 
vomiting, diarrhea, anorexia, and malaise. Alternatively, they may 
present with more specific complications of chronic liver disease, 
including ascites, edema, or upper gastrointestinal (GI) hemorrhage. 
Pruritis is an important manifestation of biliary cirrhosis.  
Other clinical manifestations include the development of jaundice 
or encephalopathy. On physical examination, the liver and spleen may be 
enlarged, with the liver edge being firm and nodular.16  
Frequent findings include scleral icterus, palmar erythema, spider 
angiomas, parotid gland enlargement, digital clubbing, muscle wasting, or 
the development of edema and ascites.  
 Men may have decreased body hair and gynaecomastia and 
testicular atrophy, which may be a consequence of hormonal 
abnormalities or a direct toxic effect of alcohol on the testes.  In women 
with advanced alcoholic cirrhosis, menstrual irregularities usually occur, 
and some women may be amenorrheic. These changes are often 
reversible following cessation of alcohol. 
SYMPTOMS: 
 Jaundice is absent in cirrhosis. It suggests either that the 
causative agent is still active or hepatic decompensation has occurred 
indicating further progression of the disease. 
Weakness, easy fatigability & tiredness are very common and 
contribute to the general malaise of cirrhosis, though objective evidence 
of weakness is unusual. Anorexia is frequently present.  
Nausea and vomiting are common and one has to look for 
remediable cause for these symptoms. Vomitus has to be examined to 
rule out hemetemisis. Abdominal pain or right hypochondrial pain or 
discomfort may be present. Tenderness may be localized to lower right 
ribs.  
 Abdomen distension is due to ascites. Fluid retention may lead to 
sacral or ankle edema.Patients may have constipation or diarrhea. 
Dyspnea may be associated with gross ascites. This can also be due to 
associated pulmonary fibrosing alveolitis, pulmonary shunting and 
pulmonary hypertension. 
Patients may often complain of nose or oral bleed. This may lead to 
hepatic encephalopathy. Fever may occur without a cause and patient can 
be depressed. In Biliary cirrhosis pruritus is seen in approximately 50% 
of patients at the time of diagnosis and can be debilitating.  
3.2.7  PHYSICAL SIGNS 
Most patients with cirrhosis look well until the late stage of the 
disease, when muscle wasting and loss of adipose tissue may become 
prominent. 
Protein-calorie malnutrition is a common complication of chronic 
liver disease, present in 20% of patients with compensated cirrhosis and 
more than 60% of those with severe hepatic dysfunction 17 
 Pallor may be due to recent UGI bleed or  iron deficiency anemia 
due to chronic blood loss. Macrocytosis (MCV) greater than 95 fl is 
presumably due to a direct effect of alcohol on bone marrow. 
 Deficiencies of folate and vitamin B12  contribute to macrocytocis in the  
malnourished patient. The combination of a raised MCV and serum g-GT 
will identify 90% of alcohol-dependent patients. 
  Eye signs. Lid retraction and lid lag is significantly increased in 
patients with cirrhosis compared with a control population18.However 
Serum-free thyroxine is not increased.  
 Parotid gland enlargement and Dupuytren’s contracture are seen in 
some alcoholic patients with cirrhosis. Digital clubbing and hypertrophic 
osteoarthropathy may complicate cirrhosis, especially biliary cirrhosis. 
These changes may be due to aggregated platelets, passing peripherally 
through pulmonary arteriovenous shunts, plugging capillaries and 
releasing PDGF.19 
 Muscle cramps occur significantly more frequently in cirrhotic 
patients than in patients without liver disease, and correlate with the 
presence of ascites and plasma renin activity.20 Splenomegaly and 
abdominal wall venous collaterals usually indicate portal hypertension. 
 Abdominal herniae are common with ascites. They should not be 
repaired unless life endangering or the cirrhosis is very well 
compensated. Spider naevi, palmar erythema, paper money skin are also 
found in cirrhosis (alcoholic). Excessive bleeding and petechiae are found 
in skin when liver function deteriorates. 
  Those with hemochromatosis may show widespread melanin 
pigmentation with localized hyperpigmentation. Vitiligo occurs in 
autoimmune hepatitits.  Dupuytern’s contracture and parotid 
enlargement are seen more commonly in alcoholic cirrhosis.  Flapping 
tremor or asterixis may be observed in patients with hepatic 
encephalopathy. Kayser Fleischer ring is seen in Wilson’s disease and is a 
potentially treatable condition. 
 
ABDOMINAL SIGNS: 
PORTAL HYPERTENSION: 
 The normal liver has the ability to accommodate large changes in 
portal blood flow without appreciable alterations in portal pressure. Portal 
hypertension results from a combination of increased portal venous 
inflow and increased resistance to portal blood flow. 
  In cirrhosis, decreased local production of nitric oxide by 
endothelial cells permits stellate cell contraction, with resulting 
vasoconstriction of the hepatic sinusoid. Increased local levels of 
vasoconstricting chemicals, like endothelin, may also contribute to 
sinusoidal vasoconstriction. The classic sinusoidal cause of portal 
hypertension is cirrhosis. 
 
 MEASUREMENT OF PORTAL HYPERTENSION: 
 Free Hepatic Vein Pressure (FHVP) is equal to inferior vena caval 
pressure. FHVP is used as an internal zero reference point. Wedged 
Hepatic Venous Pressure (WHVP) is measured by inflating a balloon at 
the catheter tip, thus occluding a hepatic vein branch. Measurement of the 
WHVP provides a close approximation of portal pressure (PP). Both the 
WHVP and PP are elevated in patients with sinusoidal portal 
hypertension, as is observed in cirrhosis. 
CONSEQUENCES OF PORTAL HYPERTENSION: 
 Ascites , Hepatic Encephalopathy 
ASCITES:   
 Ascites is defined as an accumulation of excessive fluid within the 
peritoneal cavity and may be a complication of both hepatic and 
nonhepatic diseases. When the gradient between the serum albumin level 
and the ascitic fluid albumin level is >1.1 g/dL, the cause of the ascites is 
most likely due to portal hypertension; this is most often in the setting of 
cirrhosis. When the gradient is <1.1 g/dL, infectious or malignant causes 
of ascites should be considered. 
  In exudative ascites, fluid weeps from an inflamed or tumor-laden 
peritoneum. In general, ascites protein is greater than 2.5 g/dL. Examples 
included peritoneal carcinomatosis and tuberculous peritonitis.  
The role of portal hypertension in the pathogenesis of cirrhotic ascites: 
 Normally the trans-sinusoidal oncotic gradient is approximately 
zero. The increased sinusoidal pressure that develops in portal 
hypertension increases the amount of fluid entering the space of Disse.  
The role of renal dysfunction in the pathogenesis of cirrhotic ascites 
 The peripheral arterial vasodilation hypothesis states that 
splanchnic arterial vasodilation, driven by high nitric oxide levels, leads 
to intravascular underfilling. This leads to stimulation of the renin-
angiotensin system and the sympathetic nervous system and release of 
antidiuretic hormone. 
Spontaneous bacterial peritonitis 
SBP is observed in 15-26% of patients hospitalized with ascites. 
The syndrome arises most commonly in patients whose low-protein 
ascites (<1 g/dL) since it contains low levels of complement thereby 
resulting in decreased opsonic activity. SBP appears to be caused by the 
translocation of GI tract bacteria across the gut wall and also by the 
 hematogenous spread of bacteria. The most common causative organisms 
are Escherichia coli, Streptococcus pneumoniae, Klebsiella species, and 
other gram-negative enteric organisms. 
Other complications of massive ascites 
Patients with massive ascites may experience abdominal 
discomfort, depressed appetite, and decreased oral intake. Diaphragmatic 
elevation and pleural effusion may lead to symptoms of dyspnea. 
Umbilical and inguinal hernias are common in patients with moderate and 
massive ascites. Umbilical hernias should not undergo elective repair 
unless patients are significantly symptomatic or their hernias are 
irreducible.  
INVESTIGATIONS 
Heamotology: 
Routine blood counts may be normal in cirrhosis especially early in 
cirrhosis. Mild anemia is common. On blood films target cells may be 
seen and in rare cases acanthocytes and other features of hemolytic 
anemia may be seen. 
Anemia may result from folate deficiency, hemolysis, or 
hypersplenism. Thrombocytopenia usually is secondary to hypersplenism 
 and decreased levels of thrombopoietin. If cholestasis is present it leads to 
decreased vitamin K absorption, with resulting reduction in hepatic 
production of factors II, VII, IX, and X.  
The White Blood Count tends to fall in patients with cirrhosis, due 
to hypersplenism. The platelet count is usually low in cirrhotics  again 
due to hypersplenism.  
 
BIOCHEMICAL: 
Liver Function Tests: 
 They are only of limited value in cirrhosis as they may be normal. 
Aspartate Amino Transferase (AST) and Alanine Amino Transferase 
(AST) are normal in cirrhosis especially if the causative agent is no 
longer active or because of effective treatment.  
 In alcoholics with alcoholic hepatitis and minimal cirrhosis, 
AST/ALT ratio is usually greater than 2. In most patients, Serum 
Alkaline Phophatase (SAP) is normal, except in biliary cirrhosis. 
 The levels of Gamma Glutamyl transferase levels (GGT) may be 
increased in alcoholic cirrhosis. The serum total bilirubin is usually 
 normal. An increase in bilirubin without any obvious cause suggests 
hepatic decompensation.  Low albumin levels are usually due to reduced 
hepatic synthesis.  
OTHER BIOCHEMICAL TESTS: 
 Plasma electrolytes are usually abnormal in cirrhosis and requires 
close monitoring.  Hyponatremia is common but hypernatremia is less 
common and may occur with GI bleeding, use of lactulose and with 
severe fluid restriction.  Serum potassium is usually normal in cirrhosis. 
But both hypo and hyper kalemia is observed depending upon the type of 
diuretic therapy instituted.  
COMPLICATIONS OF CIRRHOSIS: 
 The clinical course of patients with advanced cirrhosis is often 
complicated by a number of important sequelae that can occur regardless 
of the underlying cause of the liver disease. These include portal 
hypertension and its consequences of gastroesophageal variceal 
hemorrhage, splenomegaly, ascites, hepatic encephalopathy, spontaneous 
bacterial peritonitis (SBP), hepatorenal syndrome, and hepatocellular 
carcinoma. 
Table listing complications of cirrhosis 
 Portal hypertension Coagulopathy 
  Gastroesophageal varices  Factor deficiency
  Portal hypertensive gastropathy   Fibrinolysis 
  Splenomegaly, hypersplenism  Thrombocytopenia
  Ascites Bone disease  
    Spontaneous bacterial peritonitis   Osteopenia 
Hepatorenal syndrome   Osteoporosis 
  Type 1   Osteomalacia 
  Type 2 Hematologic abnormalities
Hepatic encephalopathy   Anemia 
Hepatopulmonary syndrome  Hemolysis
Portopulmonary hypertension   Thrombocytopenia 
Malnutrition  Neutropenia 
 
 
 Of these, the major ones are 
1.  Portal Hypertension and ascites 
2. Hepatic Encephalopathy 
3. Hepatocellular carcinoma 
4. Infections 
The minor complications of significance are 
1.  Fluid and Electrolyte disturbances 
2. Anemia and hemolysis 
3. Hepatorenal syndrome 
4. Hepatopulmonary syndrome 
5. Gall stone 
 
 PROGNOSIS: 
 The most common tool for gauging prognosis in cirrhosis is the 
Child-Turcotte-Pugh (CTP) system. Child and Turcotte first introduced 
their scoring system in 1964 as a means of predicting the operative 
mortality associated with portocaval shunt surgery. Pugh's revised system 
in 1973 substituted albumin for the less specific variable of nutritional 
status.24  More recent revisions use the International Normalized Ratio 
(INR) in addition to prothrombin time. 
Child-Turcotte-Pugh Scoring System for Cirrhosis  
Clinical variable 1 point  2 points   3 points 
Encephalopathy None   Stages- 1 -2   Stages3-
Ascites   Absent   Slight    Moderate 
Bilirubin (mg/dL) <2   2-3    >3  
(Bilirubin in PBC  
or PSC (mg/dL) <4   4-10    >10 
 
Albumin (g/dL) >3.5   2.8-3.5    <2.8 
Prothrombin time 
(seconds prolonged  
or INR)  <4 s or INR <1.7 4-6 s or INR 1.7-2.3  >6 s or       
                                                                                                                        INR >2. 
[Child Class A=5-6 points, Child Class B=7-9 points, Child Class C=10-15 points] 
 Recent epidemiologic work shows that the CTP score may predict 
life expectancy in patients with advanced cirrhosis. A CTP score of 10 or 
greater is associated with a 50% chance of death within 1 year. 
 
2. Cox’s Regression Model: 
 Poor prognosis is associated with  
• Prolonged prothrombin time 
• Marked ascites 
• Gastrointestinal bleed 
• Advanced age 
• Continuing alcohol consumption 
• High serum bilirubin 
• Spontaneous bacterial peritonitis 
• Ascites 
TREATMENT: 
 Specific medical therapies may be applied to many liver diseases in 
an effort to diminish symptoms and to prevent or forestall the 
development of cirrhosis. Examples include prednisone and azathioprine 
for autoimmune hepatitis, interferon and other antiviral agents for 
 hepatitis B and C, phlebotomy for hemochromatosis, ursodeoxycholic 
acid for primary biliary cirrhosis, and trientine and zinc for Wilson 
disease.  
 Once cirrhosis develops, treatment is aimed at the management of 
complications as they arise. 
Nutrition 
Many patients complain of anorexia, which may be compounded 
by the direct compression of ascites on the GI tract. Patients frequently 
benefit from the addition of commonly available liquid and powdered 
nutritional supplements to the diet. Institution of a low-protein diet in the 
fear that hepatic encephalopathy might develop may result in 
development of profound muscle wasting. 
Adjunctive therapies 
Zinc deficiency commonly is observed in patients with cirrhosis. 
Treatment with zinc sulfate at 220 mg orally twice daily may improve 
dysgeusia and can stimulate appetite. Furthermore, zinc is effective in the 
treatment of muscle cramps and is adjunctive therapy for hepatic 
encephalopathy. 
 Pruritus is a common complaint in both cholestatic liver diseases 
(eg, primary biliary cirrhosis) and in noncholestatic chronic liver diseases 
(eg, hepatitis C). Serum bile acids and endogenous opioids are more 
likely to be pruritogens.  
Cholestyramine is the mainstay of therapy for the pruritus of liver 
disease. Patients with severe pruritus may require institution of ultraviolet 
light therapy or plasmapheresis. 
Patients with cirrhosis may develop osteoporosis. Supplementation 
with calcium and vitamin D is important in patients at high risk for 
osteoporosis.  
HEPATIC ENCEPHALOPATHY 
DEFINITION 
 Hepatic encephalopathy (HE) can be defined as a disturbance in 
central nervous system (CNS) function due to hepatic insufficiency or 
portosystemic shunting25. This vague definition reflects the existence of a 
spectrum of neurologic manifestations that develop in association with 
different liver diseases.  
The encephalopathy of cirrhosis has portal-systemic shunting as a 
component but hepato-cellular dysfunction is also important; various 
 precipitating factors playing a part. Cerebral Edema is an important 
feature of acute liver failure, which often manifests with mania.  
The experts decided to classify HE into three types – A, B, and C. 
The most frequent is type C. 
Table 
Type A HE   associated with Acute liver failure 
 
Type B HE   associated with portal-systemic Bypass, 
no intrinsic hepatocellular disease 
 
Type C HE   associated with Cirrhosis and portal hypertension 
or portal-systemic shunts: 
 
– Episodic HE: precipitated, spontaneous, recurrent 
– Persistent HE: mild, severe, treatment-dependent 
-  Minimal HE 
 Patients with HE may have altered brain energy metabolism and 
increased permeability of the blood-brain barrier. Putative neurotoxins 
include short-chain fatty acids, mercaptans, false neurotransmitters (eg, 
tyramine, octopamine, and beta-phenylethanolamines), ammonia, and 
gamma-aminobutyric acid (GABA). 
Table  
 
Types of hepatic encephalopathy 
 
Type of encephalopathy   % Survival   Aetiological factors 
 
 
Acute liver failure    20*    Viral hepatitis 
Alcoholic hepatitis 
Drug reactions and 
overdose 
 
Cirrhosis with     70–80    Diuresis, Hemorrhage 
precipitant        Paracentesis, Diarrhea 
vomiting, surgery 
Alcoholic excess 
Sedatives,Infections 
 
Type of encephalopathy   % Survival   Aetiological factors 
  
Type of encephalopathy   % Survival   Aetiological factors 
Constipation 
 
Chronic portal-systemic   100    Portal-systemic shunting 
encephalopathy  Dietary protein intake & 
Intestinal bacteria 
According to the consensus arrived at the 11th World Congress of  
Gastroenterology, HE can be classified into 3 major clinical types:  
a. HE associated with acute liver failure. 
b. HE associated with portal systemic bypass and no 
intrinsic hepatocellular disease. 
c. HE associated with cirrhosis and portal hypertension/ 
or portalsystemic shunts. 
This last type can be divided in 3 subtypes: 
I. Episodic HE 
II. Persistent HE  
III.Minimal -or subclinical- HE (MHE) 
The clinical grades of hepatic encephalopathy 
I  Mild confusion, euphoria, anxiety or depression 
Shortened attention span 
Slowing of ability to perform mental tasks 
(addition/subtraction) 
Reversal of sleep rhythm 
 
II  Drowsiness, lethargy, gross deficits in ability to perform 
mental tasks 
Obvious personality changes 
Inappropriate behaviour 
Intermittent disorientation of time (and place) 
Lack of sphincter control 
 
III  Somnolent but rousable 
Persistent disorientation of time and place 
Pronounced confusion 
 Unable to perform mental tasks 
IV  Coma with (IVa) or without (IVb) response to painful stimuli 
PATHOGENISIS 
  Ideally, HE should be discussed in relation to liver abnormalities, 
neurologic disturbances, and clinical manifestations. However, 
establishing such relations is difficult. A common pathogenetic notion is 
that HE is caused by substances which under normal circumstances are 
efficiently metabolized by the liver. In patients with liver disease, these 
toxic substances reach the systemic circulation through portosystemic 
shunting or reduced hepatic clearance and produce deleterious effects on 
brain function.  
Historical hypotheses have ranged from single unifying theories26 
to the notion of HE as a multifactorial process27. A unique feature of HE 
is the abnormality of astrocyte morphology and function. This feature has 
led to a view that in HE the abnormality in consciousness is the 
consequence of altered astrocyte–neuronal communications28. 
Alternative views, such as the γ-aminobutyric acid (GABA) theory, 
explain the spectrum of HE through the direct effect of a toxin on a key 
aspect of neurologic function29. Other paradigms arise from the 
experimental observation that different toxins (e.g., fatty acids or 
mercaptans) enhance the negative effects of ammonia on consciousness 
 (synergistic theory). Finally, current views also emphasize differing 
effects of different toxins at various neurologic levels. For example, 
manganese appears to be involved in Parkinsonian manifestations but not 
in decreasing arousal.  
At present, the main substances considered to be implicated in the 
development of HE are ammonia and other intestinal neurotoxins, 
manganese and the  Benzodiazepine- GABA system1. However, 
alterations in neurotransmission are probably the main cause of HE.   
Ammonia possibly plays a major role in these abnormalities. At present, 
it is difficult to ascribe changes in other neurotransmission systems that 
have been detected in HE to the clinical manifestations of this syndrome. 
Pathology and Neuroimaging in HE 
 
 
Although HE is a functional syndrome, the most common 
pathological finding in patients with advanced or persistent HE is the 
presence of the so-called Alzheimer’s type II astrocytosis because of an 
increase in intracellular water that is produced by the hyperammonemia.30  
On magnetic resonance spectroscopy (MRS), the cerebral 
concentrations of glutamine are high and those of myoinositol low, 
reflecting the activation of the osmoregulation.   
The role of neuroimaging in the study of HE is stressed by the 
finding of the previously mentioned changes in MRI  or MRS. Positron 
 emission tomography (PET) has also been used in the study of the 
pathophysiological mechanisms of HE.  
 MRI showing Globus pallidus hyperintensity in T2 weighted image 
 
The essentially reversible nature of the syndrome with such 
widespread cerebral changes suggests a metabolic mechanism. However, 
no single metabolic derangement accounts for hepatic encephalopathy. 
Several neuroactive toxins, in particular ammonia, and neurotransmitter 
systems are thought to be involved and inter-relate.  
 
Neurotransmission 
 
Although there are many studies in experimental and human 
encephalopathy, the overall picture remains complex and in many areas 
conflicting and controversial. Definitive data are difficult to collect. 
 
 
Ammonia and glutamine 
 
Ammonia is produced from the breakdown of proteins, amino 
acids, purines and pyrimidines. About half of the ammonia arising from 
the intestine is synthesized by bacteria, and the remainder comes from 
 dietary protein and glutamine. The liver normally converts ammonia to 
urea and glutamine through the urea cycle.  
In hepatic encephalopathy blood ammonia levels are elevated in 
90% of patients. Brain levels of ammonia are also increased. 
Encephalopathy can be reproduced in some patients by oral ammonium 
salts.  
Hyperammonaemia per se is associated with decreased excitatory 
neurotransmission. Ammonia intoxication leads to a hyperkinetic 
preconvulsive state which cannot be equated with hepatic coma. The 
primary mechanisms proposed for ammonia as a case of hepatic 
encephalopathy are a direct effect on neural membranes or on post-
synaptic inhibition31, and an indirect neuronal dysfunction.  
There is no urea cycle in the brain, and ammonia removal involves 
a different pathway. In astrocytes, glutamine synthetase converts 
glutamate plus ammonia to glutamine. With excess ammonia, glutamate 
(an important excitatory neurotransmitter) is depleted, and glutamine 
accumulates. 1H (proton) MRS studies in hepatic encephalopathy show 
changes consistent with an increase in cerebral glutamine32,33 The overall 
contribution of ammonia to the development of hepatic encephalopathy is 
difficult to quantify, particularly since there are also changes in other 
neurotransmitter systems.  
 Methionine derivatives, mainly mercaptans, induce hepatic 
encephalopathy. This has led to the view that certain toxins, particularly 
ammonia, mercaptans, fatty acids and phenols, act synergistically. These 
observations need evaluation with the better techniques now available. 
Manganese 
Blood and brain concentrations of manganese are increased in 
chronic liver failure. Manganese deposition is the most likely explanation 
for the hyper-intensity on MRI of the globus pallidus. Exposure of 
astrocytes to manganese produces Alzheimer type 2 changes as seen in 
hepatic encephalopathy.  
False neurotransmitters 
It has been proposed that dopamine and catecholamine mediated 
cerebral neurotransmission is inhibited by amines generated either by 
bacterial action in the colon or by the altered cerebral metabolism.  The 
original hypothesis suggested that decarboxylation of some amino acids 
in the colon leads to the formation of b-phenylethanolamine, tyramine 
and octopamine so-called false neurotransmitters. These might replace 
the true transmitter.  
An alternative approach to interference with normal 
neurotransmission is based on a change in the availability of precursors.. 
An increase in phenylalanine level in the brain leads to inhibition of dopa 
 production and the formation of false neurotransmitters such as 
phenylethanolamine and octopamine. 
A change in this neurotransmitter system in hepatic encephalopathy 
has some support, since there is improvement after L-dopa and 
bromocriptine treatment. Serum and urinary octopamine levels are 
increased in hepatic encephalopathy.  
 
Serotonin 
 
Serotonin (5-hydroxytryptamine or 5-HT) is involved in the control 
of cortical arousal and thus the conscious state and the sleep/wake cycle. 
It is also increased in the CSF and brain of patients with hepatic coma. In 
hepatic encephalopathy there are also other changes in serotonin 
metabolism including related enzymes (monoamine oxidase, MAO), 
receptors and metabolites (5-hydroxyindole acetic acid, 5-HIAA).  
g-Aminobutyric acid (GABA) and endogenous benzodiazepines 
GABAis the principal inhibitory neurotransmitter in the brain. It is 
usually synthesized from glutamate by glutamate dehydrogenase in 
presynaptic nerves and stored in vesicles. It binds to a specific GABA 
receptor in the postsynaptic membrane causing neuro-inhibition. 
 GABA is synthesized by gut bacteria, and that entering the portal 
vein is metabolized by the liver. There are increased GABA levels in the 
plasma of patients with liver disease and hepatic encephalopathy.  
 
 
Simplified model of the GABAreceptor/ ionophore complex embedded in a postsynaptic neural membrane. 
Binding of any of the depicted ligands, gaminobutyric acid (GABA), barbiturates (BARB) or benzodiazepines 
(BZP), to its specific binding site increases chloride ion conductance through the membrane with resultant 
hyperpolarization and neuroinhibition 
 
However, the focus on the GABA–benzodiazepine receptor suggest that 
endogenous benzodiazepines are present in patients with hepatic 
encephalopathy and that these may interact with the receptor complex and 
cause neuroinhibition. Stool from cirrhotic patients contains five times 
the benzodiazepine-like activity as stool from controls34.  
Both central benzodiazepine receptors (coupled GABA-A 
receptors) and peripheral type benzodiazepine receptors are increased in 
the brain in chronic liver failure. Flumezanil, a benzodiazepine antagonist 
is hence useful for treatment.37 
 
 
 Other metabolic abnormalities 
Neuronal nitric oxide synthase may be increased in hepatic 
encephalopathy and make a contribution to the altered cerebral perfusion 
in chronic liver disease. 
These patients are often alkalotic. This may result from toxic 
stimulation of the respiratory centre by ammonium, from administration 
of alkalis such as citrate in transfusions or with potassium supplements, 
or from hypokalaemia. Urea synthesis also consumes bicarbonate.  
Hypoxia increases cerebral sensitivity to ammonia Hypocapnia 
follows and this reduces cerebral blood flow. The increase in the blood 
organic acids (lactate and pyruvate) is correlated with the reduction in 
CO2 tension.  
Changes in carbohydrate metabolism 
 Hypoglycaemic episodes are rare in chronic liver disease but may 
complicate fulminant hepatitis. 
a-Ketoglutaric and pyruvic acids are transported from the periphery 
to the metabolic pool in the liver, and blood levels increase as the 
neurological state deteriorates. These levels probably reflect severe liver 
damage. The fall in blood ketones also reflects severity of hepatic 
dysfunction.  
 
 Astrocyte swelling 
Studies using MR spectroscopy show ‘osmolytes’. It has been 
suggested that an associated increase in astrocyte hydration may be a 
major pathogenetic event in the development of hepatic encephalopathy  
 
 
Multifactorial mechanism of hepatic encephalopathy. The altered neurotransmitter state leaves the brain 
more sensitive to other insults including narcotics, sepsis, hypoxia and hypotension. BZ, benzodiazepines; 
GABA, g-aminobutyric acid. 
Conclusions 
No single mechanism explains hepatic encephalopathy. The brain 
controls neuropsychiatric behavior through multiple inhibitory and 
stimulatory receptor mediated pathways. Although neurotransmitters are 
produced locally they depend upon substrates and influences from further 
afield. When the liver fails or there is portal-systemic shunting there is a 
complex pattern of changes which influence multiple neurotransmitter 
systems.  
 The effects of ammonia appear central to hepatic encephalopathy.  
Changes in glutamate, serotonin and endogenous benzodiazepine- 
mediated neurotransmission awaiting further study. The place of false 
neurotransmitters and GABA appears controversial.  
Cerebral metabolism is undoubtedly abnormal in liver disease. This 
is thought to be an effect rather than the cause of neurotransmitter-
mediated changes. In the chronic case, actual structural changes in the 
brain can be demonstrated. The end result is a brain with abnormal 
neurotransmitter function, which is unduly sensitive to insults, (opiates, 
electrolyte imbalance, sepsis, hypotension, hypoxia) that would be 
without effect in the normal patient. 
Treatment of hepatic encephalopathy  
Treatment is broadly divided into three areas.  
1 Identification and treatment of the precipitating cause. 
2 Intervention to reduce the production and absorption of gut-
derived ammonia and other toxins.  
3 Prescription of agents to modify neurotransmitter balance directly 
(bromocriptine, flumazemil), or indirectly (branched-chain amino 
acids). These are of limited clinical value at present.  
The choice of treatment depends on the clinical picture: subclinical, 
acute or persistent chronic encephalopathy. 
 
 Table 
Acute 
Identify precipitating factor 
Empty bowels of nitrogen-containing materials 
stop haemorrhage 
phosphate enema 
Protein-restricted diet; raise dietary protein slowly with recovery 
Lactulose or lactilol 
Neomycin 1g four times a day by mouth for 1 week 
Maintain calorie, fluid and electrolyte balance 
Stop diuretics, check serum electrolyte levels 
 
Chronic 
Avoid nitrogen-containing drugs 
Protein, largely vegetarian intake, at limit of tolerance 
Ensure at least two free bowel movements daily 
Lactulose or lactilol 
Diet  
 
In the acute attack dietary protein is reduced to 20g/day. Calorie 
intake is maintained at 2000cal/day or above, orally or intravenously. 
During recovery, protein is added in 10g increments on alternate days. 
Any relapse is treated by a return to the previous level.  
It is important in cirrhotic patients to avoid protein restriction for a 
period any longer than is necessary since these patients have a higher than 
normal protein requirement (1.2 g/kg/day) to maintain in positive 
balance.  
If animal protein is not well tolerated, vegetable protein may be 
used. The latter is less ammoniagenic and contains small amounts of 
methionine and aromatic amino acids.  
 Antibiotics 
Neomycin, given orally, is very effective in decreasing 
gastrointestinal ammonium formation. Little Neomycin is minimally 
absorbed from the gut although blood levels have been detected and 
impaired hearing or deafness may follow its long-term use. Neomycin 
should be used with particular caution in patients with renal insufficiency. 
In acute hepatic coma, lactulose is given, and neomycin added if the 
response is slow since the two drugs seem to act synergistically38. 
Metronidazole (200mg four times per day orally) seems to be as 
effective as neomycin. Rifaximin, a non-absorbed derivative of 
rifamycin, is effective for grade 1–3 hepatic encephalopathy at a dose of 
1200mg/day. 
Lactulose and lactilol 
The human intestinal mucosa does not have an enzyme to split 
these synthetic disaccharides. When given by mouth lactulose reaches the 
caecum where it is broken down by bacteria predominantly to lactic acid. 
The osmotic volume of the colon is increased. The faecal pH drops. The 
growth of lactose-fermenting organisms is favoured and organisms such 
as bacteroides, which are ammonia formers, are suppressed.  
The colonic fermentative bacteria prefer lactulose to blood when 
both are present. It may ‘detoxify’ short-chain fatty acids produced in the 
 presence of blood and proteins. Faecal acidity would reduce the 
ionization and hence absorption of ammonia; however faecal ammonia is 
not increased. Lactulose more than doubles the colonic output of bacterial 
mass and ‘soluble’ nitrogen which is then no longer available for 
absorption as ammonia. 
The aim of treatment with lactulose is to produce acid stools 
without diarrhoea. The dose is 10–30ml three times a day and is adjusted 
to produce two semi-soft stools daily. This improves level of 
consciousness44. 
Lactilol (b-galactoside sorbitol) is a second-generation disaccharide 
easily produced in chemically pure crystalline form, which can be 
dispensed as a powder. It is not broken down or absorbed in the small 
intestine, but is metabolized by colonic bacteria. Lactilol seemed to be as 
effective as lactulose in chronic and acute portal-systemic 
encephalopathy.39 
Lactulose or lactose enemas may be used and are superior to 
water41. All enemas must be neutral or acid to reduce ammonium 
absorption. Magnesium sulphate enemas can cause dangerous 
hypermagnesaemia. Phosphate enemas are safe. 
 
 
 Sodium benzoate and L-ornithine -L-aspartate 
Sodium benzoate promotes urinary excretion of ammonia and is as 
effective as lactulose and is less expensive. L-ornithine-L-aspartate 
treatment promotes hepatic removal of ammonia by stimulating residual 
hepatic urea cycle activity and promoting glutamine synthesis, 
particularly in skeletal muscle42 and helps in improving level of 
consciousness. 
Levodopa and bromocriptine 
  If portal-systemic encephalopathy is related to a defect in 
dopaminergic neurotransmission then replenishment of cerebral 
dopamines should be beneficial. Dopamine does not pass the blood–brain 
barrier, but its precursor, levodopa, does and can cause temporary arousal 
in acute hepatic encephalopathy43.  
Flumazenil 
This is a benzodiazepine-receptor antagonist which can induce 
transient, variable but distinct improvement in some patients with hepatic 
encephalopathy associated with fulminant liver failure or cirrhosis37. 
Overall results showed improvement in neurological score in 15% of 
treated patientcompared with 3% on placebo. EEG improved in 25% of 
treated patients compared with 4% on placebo.  
Branched-chain amino acids 
 In cirrhotic patients the serum branched chain amino acids valine, 
leucine and isoleucine are low, and aromatic amino acid levels are 
increased. The reduced ratio of branched-chain to aromatic amino acids 
has been related to the development of hepatic encephalopathy through 
increased supply of precursors of neurotransmitters.  
Infusions of solutions containing a high concentration of branched-
chain amino acids have been used to treat acute and chronic hepatic 
encephalopathy with conflicting results. 
Other precipitating factors 
Patients are extremely sensitive to sedatives and whenever possible 
these are avoided. If an overdose is suspected, the appropriate antagonist 
should be given. If the patient is uncontrollable and some sedation is 
necessary, a small dose of temazepam or oxazepam is given; morphine 
and paraldehyde are absolutely contraindicated.  
Drugs known to induce hepatic coma such as oral amino acids and 
diuretics are disallowed. Potassium deficiency can be treated by fruit 
juices or by effervescent or slow-release potassium chloride.  
 
 
 
 
 Temporary hepatic support 
Complicated methods of temporary hepatic support are not 
applicable to hepatic coma in the cirrhotic. Such a patient is either 
terminal or can be expected to come out of coma without them. 
Hepatic transplantation 
This may be the ultimate answer to the problem of chronic hepatic 
encephalopathy. One patient with a history of 3 years showed marked 
improvement lasting 9 months following transplantation. Another patient 
with chronic hepato-cerebral degeneration and spastic paraparesis showed 
remarkable improvement after orthotopic liver transplantation. 
 
MINIMAL HEPATIC ENCEPHALOPATHY 
 
 
MHE is defined as the condition in which patients with liver 
cirrhosis show several quantifiable neuropsychological defects together 
with a normal neurological examination. 
 The pathogenesis of MHE is not yet clear. Subcortical alterations 
in the basal ganglia has been suggested as a possible anatomical site 
responsible for the subclinical changes of this entity.8The selective 
reduction in glucose consumption in the area of the cyngulate gyrus, a 
nucleus involved in the attention process, coupled with focal alterations 
of cerebral perfusion support this hypothesis.9 
 The relation of subclinical changes to protein metabolism and 
plasma amino acid imbalance, the reduction in cerebral blood flow and 
the improved response of neuropsychological tests after therapeutic 
manipulations (which are applied in clinically overt HE), suggest the 
impact of the liver disease on brain function.7 The incidence of MHE is 
estimated to vary from 30% to 84% in apparently healthy, non-
encephalopthic cirrhotic patients, depending on the diagnostic criteria 
used.10 
The Cerebral Blood Flow range in healthy young subjects (age, 23-
42 years) was 44-61 m1/100 g/min; in patients with grade I + II 
encephalopathy (mean ± SEM) it was 32.8 23.6 m1/100 g/min in acute 
(age, 28 ± 8 years) and 37.0 .3.3 m1/100 g/ min in chronic liver patients 
(age, 51 ± 2 years). In grade III ± IV encephalopathy it was 28.7 ± 3.8 
m1/100 g/min in acute (age, 28 ± 3 years) and 32.9 ± 3.7 m1/100 g/min in 
chronic patients (age, 49 ± 3 years). A marked reduction of the CBF was 
seen in hepatic encephalopathy, irrespective of the etiology of the 
disease.10 
Fifty percent of the patients had an abnormal Number Connection 
Test according to the standard recommended procedure, in contrast only 
7% of the patients had an abnormal NCT when scores corrected for age 
were used.  
 Combining the results of the spectral EEG and the psychometric 
tests corrected for age yielded a higher prevalence of SHE (23%) than 
when each test method was used alone (17% vs. 10% abnormal, 
respectively). Severity of liver disease correlated with the presence of 
SHE, because the prevalence of abnormal tests increased from 14% in 
Child-Pugh grade A to 45% in Child-Pugh grade B or C. Age above 40 
years and an elevated blood ammonia level were significant determinants 
related to an abnormal EEG. Using a combination of spectral EEG and 
two psychometric tests with age-corrected normal values a low 
prevalence of SHE in patients with Child A liver cirrhosis was found. 
Older patients with an elevated arterial ammonia are more prone to 
develop SHE than younger patients with an equal arterial ammonia 
concentration.12.13 
Although the diagnosis of symptomatic HE is a diagnosis of 
exclusion, based mainly on a careful global and neuropsychiatric 
examination, MHE is not a clinically evident entity and thus, for their 
detection, requires specific neuropsychological and neurophysiological 
examination.14 
 The interest in identifying MHE has made researchers to 
formulate and use 60 tests and eight batteries in various studies. These 
can be divided into four major groups.15 
 I. Psychometric or Neuropsychological tests 
II. Electrophysiological or Neurophysiological tests 
III. Neuroimaging testing 
IV. Tests of cerebral metabolism 
I. PSYCHOMETRIC OR NEUROPSYCHOLOGICAL TESTS 
Based on the hypothesis that mental changes can precede overt 
neurological symptoms of HE., Zeegen et al in the early 1970.s, first 
demonstrated an abnormal score in approximately one third of 39 
apparently healthy cirrhotic patients previously operated for portal 
decompression, using the Reitan trail making tests. 
The statement of the Consensus Conference of the 11th World  
Congress of Gastroenterology proposed that at least two of the following 
psychometric examinations should be used: NCT-A, NCT-B, BlDes, 
DST. A standardized test battery that includes the NCT-A and -B, the 
line-tracing test, the serial-dotting test and the DST is recommended6. 
The newly developed computerized psychometric tests, Posner test,   
Ternberg Paradigm appear to be very promising tools, but experience is 
still limited.  
 
 
 2.  ELECTROPHYSIOLOGICAL OR NEUROPHYSIOLOGICAL 
    TESTS 
Although EEG is the most widely used neurophysiological  
diagnostic tool for the detection of clinically apparent HE, its diagnostic 
role in MHE is minor. With a percentage of abnormal examinations 
ranging between 8%-35% among cirrhotics without overt HE, it is 
considered less sensitive than psychometric tests7 
Apart from EEG, several investigators have used evoked potentials 
(EP) such as the P300 (P300 eventrelated potentials), the SSEP 
(somatosensory-evoked potentials), the BAEP (brain stem auditory-
evoked potentials) and the VEP (visual-evoked potentials) can be used21. 
The P300 examination is an endogenous EP that is regarded as  
representing stimulus evaluation processes. In contrast to the 
conventional EPs, the response on P300 does not depend on the physical 
properties of the stimulus, but rather on the meaning of the stimulus to the 
patient. In this test, the response to two different stimuli, visual and 
acoustic, is measured and the patient is asked to identifity a predefined 
stimulus. A prolongation of the P300 latency to acoustic stimuli is 
observed in patients with MHE. 
 
 
 
 
 3.  NEUROIMAGING TESTS 
 
 
Brain imaging provides no useful information for the assessment of  
MHE. Computer tomography must be used only for differential 
diagnosis.  
Although cranial magnetic resonance imaging shows characteristic  
abnormalities in cirrhotic patients (symmetric pallidal hyperintensities in 
T1-weighted images), these changes do not correlate with the grade of 
encephalopathy. Proton magnetic resonance spectroscopy and positron 
emission tomography (PET) are two relatively new imaging methods and 
the experience in diagnosis of MHE with these is very limited.9 
4.  TEST OF CEREBRAL METABOLISM 
There is a very little data about tests of cerebral metabolism in  
diagnosis of MHE. 
 
CLINICAL SIGNIFICANCE OF M.H.E. 
 
Impact on daily life:  
The significance of MHE diagnosis is still a subject of debate. 
Several investigators have reported a negative influence on daily 
functioning. Other studies suggest a possible relation between MHE and 
the subsequent development of episodes of overt HE.  
The reduction in the ability of these patients to carry out activities 
(driving a car, performing at work) probably reflects the 
 neuropsychological deficits founded in MHE. It has been reported that a 
percentage of between 44% and 70% of cirrhotics with the diagnosis of 
MHE show an impairment in their ability to drive an automobile. On the 
other hand, other investigations, did not revealed differences in quality of 
automobile driving between cirrhotics with MHE and healthy subjects.48  
Quality of life: 
Patients with MHE experience a poor quality of life with serious 
difficulties in sleep, hobbies, recreation and deterioration of body care. 
The performance of SIP (Sickness Impact Profile) questionnaires showed 
highest scores of disability on the areas of social interaction, alertness, 
emotional behavior, mobility, sleep/rest, home management and 
recreation and pastimes. Sleep abnormalities are frequent in all cirrhotics 
and may be related to alterations of circardian function, or could reflect 
anxiety and depression as a result of living with chronic disease.  
Although named “minimal”, minimal hepatic encephalopathy 
(MHE) can have a far-reaching impact on quality of life, ability to 
function in daily life and progression to overt hepatic encephalopathy. 
Importantly, MHE has a profound negative impact on the ability to drive 
a car and may be a significant factor behind motor vehicle accidents. A 
crucial aspect of the clinical care of MHE patients is their driving history, 
which is often ignored in routine care and can add a vital dimension to the 
 overall disease assessment. Driving history should be an integral part of 
care in patients with MHE. 
 
The prognostic value of MHE:  
The clinical repercussions of detecting MHE are still unknown. A 
possible prognostic value of psychometric alterations in the subsequent 
development of overt HE and survival is suggested by several authors, 
but very few studies can confirm these statements. Most of these have 
been limited to patients with advanced liver disease (portal systemic 
shunts, decompensated cirrhosis), and the follow up time was very short: 
less than 12 months. Only two long term follow up studies have 
confirmed that MHE is an independent risk factor for the development of  
HE.  The predictive value of MHE on survival is also a subject of debate 
and the relationship between severity of liver disease and psychometric 
alterations is not yet clarified. 
 
 
 
 
 The Number Connection Test 
¾ Assesses the ability of the patient to connect a series of numbers 
from 1 to 25 
¾ Evaluates the cognitive and psychometric functions 
¾ Graded according to the time taken for the completion of the test 
and the time taken for correction of errors. 
¾ Grading  
0  - 15 – 30 sec 
1 - 31 – 50 sec 
2 - 51 – 80 sec 
3 - 80 – 120sec 
4 -  > 120 sec 
Arterial Ammonia 
 Arterial estimation more useful and correlates better with 
encephalopathy than venous levels. 
 Normal values range between 9 – 33 micromoles/litre 
Electroencephalographic Analysis 
 EEG shows  Generalised slow electrical activity  
 High amplitude low frequency waves and triphasic waves are 
significant. 
Other Assessment: 
 Evoked potential show abnormality in 90% patients. 
Positron Emission Tomography and Magnetic Resonance Spectroscopy 
are more specific for diagnosis. 
 
 
 
 
 
  
  
 
MATERIALS AND METHODS 
 4.  MATERIALS AND METHODS 
 The study was conducted in the Coimbatore Medical College 
Hospital, Coimbatore. The cases were selected from the general medical 
wards, the intensive care unit and the Medical Gastroenterology out 
patient department. 
 50 cases of compensated cirrhosis were chosen over a time span of 
6 months. 50 healthy controls were chosen from the volunteers.  Only 
patients with Ultra-sound proven cirrhosis were chosen to be included in 
the study. Patients with signs of liver decompensation like jaundice, 
history of previous admissions for hepatic encephalopathy, massive 
Gastro-intestinal bleed were excluded from the study. Patients who 
developed features of hepatic encephalopathy were excluded from the 
study. 
 Patients with other co-morbidity like severe congestive cardiac 
failure or renal failure or severe respiratory failure were also excluded. 
 42 males and 8 females were finally included as the study 
population. 
 A detailed history was recorded giving special emphasis to rule out 
any subtle performance impairment. Detailed history was also taken to 
 probe into the etiology of cirrhosis.A detailed clinical examination was 
done to rule out any signs of decompensation. Minimal ascites was not 
taken as an exclusion criteria. 
 Minimal evidence of portal hypertension was not taken as 
exclusion criteria. 
 All the baseline investigations were done and a CNS examination 
carried out to rule out other causes of encephalopathy. Patients above 75 
years of age were excluded as the incidence of dementing illness was 
high in the age group. 
 A number connection test was given to the patient and the control 
simultaneously. After proper explanation of the procedure test was 
administered. Before interpreting the results it was made sure that they 
understood the procedure properly. The time taken to complete the test 
was added to the time taken to correct errors added. 
 An arterial blood sample was obtained from radial artery and was 
sent for ammonia analysis and an electroencephalogram was performed 
in all study subjects and in 10 healthy controls. 
The studies, especially the number connection test were repeated 
just before discharge of the patients after treatment.  
  
 
 
 
 
 
 
 
 
 
RESULTS AND ANALYSIS 
 RESULTS AND ANALYSIS 
NUMBER CONNECTION TEST: 
¾ All controls completed the NCT correctly within 60 (Normal) 
seconds 
¾ Any time greater than 60 seconds was taken as significant and an 
indication of MHC 
¾ 36% of cases were found positive (time more than 60 seconds) by 
the test 
The grading system commonly followed is as follows 
GRADE 
NCT completion 
time in seconds 
Remarks 
0 15 to 30 No MHE 
1 31 to 50 High normal 
2 51 to 80 Suggests MHE 
3 81 to 119 Highly suggests 
MHE 4 >120 
     Table.1 
The prevalence of MHE in compensated cirrhosis by the number 
connection test is given in the following tables 
 PREVALANCE OF MHC IN CIRRRHOTICS BY NCT 
NCT POSTIVE NUMBER PERCENTAGE 
Males 15 30% 
Females 2 4% 
Total 17 36% 
      Table.2 
SERUM AMMONIA 
¾ Arterial blood for estimation of Ammonia analysis was done 
¾ 15 patients whose blood was drawn for Arterial Blood Gas analysis 
(ABG) was taken as controls. None were having liver cirrhosis or 
hepatic encephalopathy 
¾ The normal ammonia level standardized for the laboratory was 10 
to 30 micro mol/litre 
¾ Any value above 30 micro mol/l was taken as positive 
¾ 50% cases were found to have positive ammonia levels (> 33 
mciromols) none in controls. 
 
 
 PREVALANCE OF MHC BASED ON AMMONIA ANALYSIS 
ARTERIAL 
AMMONIA > 30 
µmol/L 
NUMBER PERCENTAGE 
Male 18 36% 
Female 6 12% 
Total 25 48% 
     Table.3 
ELECTROENCEPHALOGRAPHY (EEG) 
¾ All 50 patients and 10 controls were taken up for EEG analysis 
¾ None of them were on sedatives or any cerebroactive drugs and 
none were epileptic 
¾ All other causes for encephalopathy were ruled out by clinical 
examination and baseline investigation 
 
EEG was taken as significant if any of the following were present: 
1. Diffuse slowing of waves 
2. High amplitude, low frequency waves 
3. Triphasic waves 
 ¾ 4 of the patients had significant findings (8%) 
¾ None of the controls had any of these findings 
 
PREVALENCE OF MHE BASED ON EEG ANALYSIS 
EEG CHANGES 
POSITIVE NUMBER PERCENTAGE 
Male 3 6% 
Females 0 0% 
Total 3 3% 
     Table.4 
 
 
 
 
 
 
 PREVALENCE OF MHE IN CIRRHOSIS USING A 
COMBINATION OF TESTS 
NAME OF TESTS NUMBER POSITIVE PERCENTAGE 
Number connection 
Test + EEG 
Males       :    3 
Females    :    0 
Total         :    3 
Males     :    6% 
Females :     0% 
Total      :     6% 
Number connection 
test + Arterial 
Ammonia 
Males        :    15 
Females    :     1 
Total         :     7 
Males     :     30% 
Females :      2% 
Total      :      32% 
EEG + Arterial 
Ammonia 
Males        :     2 
Females    :      0 
Total        :      2
Males     :      4% 
Females :       0% 
Total      :       4% 
NCT + Arterial 
Ammonia + EEG 
Male         :      2 
Females    :      0 
Total         :      2 
Males     :      4% 
Females :       0% 
Total      :       4% 
      Table.5 
 
 
 
  
  
 
 
 
 
 
 
 
OBSERVATION 
 PREVA
By NCT
 
PREVA
 
Total
62%
LENCE O
 
LENCE O
Norm
F MHE 
F MHE 
al 44%
IN MALE
IN MALE
S WITH 
S WITH 
Ma
Female 4
M
Fe
N
CIRRHO
CIRRHO
le, 32%
%
ale
male
ormal
Male
38%
Male To
SIS 
 
SIS 
 
tal
P 
PREVA
REVALE
LENCE O
NCE OF
MHE
MHE 38%
F MHE 
 MHE IN
 36
IN FEMA
 PATIENT
 
LES WIT
S WITH
No
N
M
Normal 
H CIRRH
 CIRRHO
rmal, 64
ormal
HE
62%
Normal
MHE
OSIS 
SIS 
 
 
  
 
 
 
 
 
 
 
DISCUSSION 
 6.DISCUSSION 
¾  In this study 50 cases of compensated cirrhotics were evaluated for 
presence of Minimal Hepatic Encephalopathy. 
 
¾ In this study we defined minimal hepatic encephalopathy based on 
psychometric analysis,13 by way of the Number Connection Test, 
since earlier studies have proved that the abnormal psychometric 
test as one of the earliest manifestation of minimal hepatic 
encephalopathy. Based on the NCT this study found a prevalence 
of 38%  MHE amongst the compensated cirrhotics studied 
 
¾  Minimal hepatic encephalopathy was defined in our study based 
on the prolonged time taken to complete the NCT and/or 
Electroencephalography changes/ or a combination of 
electroencephalography and serum ammonia rise/ or a combination 
of serum ammonia and number connection test. 
 
 ¾  High serum ammonia alone was not taken as indicative of minimal 
hepatic encephalopathy as it was found by many studies not to 
correlate with the presence of Minimal hepatic encephalopathy. 
 
¾  The total percentage of cases diagnosed as having minimal hepatic 
encephalopathy in our study using the above criteria was 38% 
 
¾ Out of the 19 patients tested positive for minimal hepatic 
encephalopathy 16 were males and 3 were females 
 
¾  In a study conducted by Quero et.al in Holland13 about MHE in  
cirrhotics with NCT and EEG, showed a prevalence of 24%. 
Correlation was done using arterial ammonia and PET scan. 
Magnetic Resonance Spectroscopy was also used for correlation. 
 
¾  In a German study47 published in the Journal of Hepatology in 
1998 July, pages 45 to 49 volume 28 No.1 the prevalence of MHE 
was estimated to be 45% by various psychometric tests including 
 the Number Connection Test thus establishing it as a simple 
bedside tool for assessment of the presence of MHE in the 
cirrhotics 
  
¾ In a study conducted by Amodio et al in Italy46 it was found that 
using the NCT and Line tract test the prevalence of Minimal 
Hepatic encephalopathy was estimated to be 28% but estimates by 
spectral EEG was only 10% 
 
¾ In comparison, our study shows a prevalence of minimal hepatic 
encephalopathy in the group by number connection test to be 34% 
and that by electroencephalogram to be 6%. 
 
 
 
 
  
  
 
 
 
 
 
 
CONCLUSION 
 7. CONCLUSIONS 
¾ The prevalence of Minimal Hepatic Encephalopathy in 
compensated cirrhotics in our study is 38%. 
  
¾ There is no significant difference in the prevalence rate 
between males and females. (38% Vs 37%) 
 
¾ Number Connection Test and other psychometric tests are  
useful as bedside tools in estimating Minimal Hepatic Encephalopathy. 
 
¾ Psychometric test positivity does not correlate well with 
Electro-encephalographic changes in the diagnosis of Minimal Hepatic  
Encephalopathy. 
 
¾ Evaluating a cirrhotic patient for MHE is essential for its 
impact on day to day functionality like driving, operating machineries  
and social interaction apart from other activities like driving. 
 
